Effects of Esketamine and Magnesium Sulfate on Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Placebo-Controlled, 2×2 Factorial Trial.
- 1Department of Anesthesiology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu, 223002, People's Republic of China.
Abstract
Purpose
This 2×2 factorial trial aimed to evaluate the main effects and interaction of esketamine and magnesium sulfate on postoperative fatigue syndrome (POFS) in patients undergoing laparoscopic cholecystectomy (LC).Patients and methods
In this randomized, double-blind, 2×2 factorial trial, 128 patients scheduled for elective LC were randomized to receive intravenous esketamine (0.25 mg/kg load, 0.125 mg/kg/h maintenance), magnesium sulfate (30 mg/kg load, 10 mg/kg/h maintenance), both, or placebo. The primary outcome was the Christensen Fatigue Scale (CFS) score on postoperative day 1 (POD 1). Secondary outcomes included longitudinal CFS and Identity-Consequence Fatigue Scale (ICFS) scores, Quality of Recovery-15 (QoR-15), pain scores, intraoperative hemodynamics, anesthetic consumption, and safety profiles. All randomized participants were included in the primary intention-to-treat analysis. Main effects and interactions were evaluated using generalized linear models (GLM), generalized estimating equations, and linear mixed-effects models. ClinicalTrials.gov: NCT07131033 (registered August 13, 2025).Results
Of the 128 randomized patients, 10 were excluded, leaving 118 in the per-protocol set, which was used only as a descriptive sensitivity analysis. Based on the prespecified factorial GLM, both esketamine and magnesium sulfate exhibited significant main effects in reducing POD 1 CFS scores (esketamine: mean difference [MD], -1.12; 95% confidence interval [CI], -1.69 to -0.55; P < 0.001; magnesium sulfate: MD, -0.69; 95% CI, -1.26 to -0.12; P = 0.018), with no significant interaction (P = 0.592). In the longitudinal analysis, esketamine reduced CFS scores on POD 1 (MD, -1.17; P = 0.001), whereas the magnesium sulfate contrast at POD 1 was not statistically significant after Bonferroni correction (MD, -0.71; P = 0.300). Neither drug significantly affected ICFS scores (P > 0.05). Esketamine improved QoR-15 scores on POD 1 and POD 2, with MDs of 10.41 (P < 0.001) and 4.60 (P = 0.001) points, respectively. Magnesium sulfate improved QoR-15 scores on POD 1 by 7.48 points (P < 0.001) but not on POD 2. Both interventions decreased early postoperative pain and intraoperative propofol and remifentanil consumption (P < 0.001). Magnesium sulfate significantly prolonged extubation time (MD, 1.69 min; 95% CI, 0.26 to 3.12; P = 0.021), whereas esketamine did not reach statistical significance; neither agent significantly increased PACU stay. No significant differences were observed in prespecified adverse events.Conclusion
In this 2×2 factorial trial, perioperative esketamine was associated with reduced acute postoperative fatigue and improved early recovery after laparoscopic cholecystectomy, whereas the magnesium sulfate effect was significant in the GLM model but not confirmed by the corrected longitudinal analysis. Both agents had anesthetic-sparing and early analgesic effects, and no significant esketamine-magnesium interaction was detected for the primary outcome. Magnesium sulfate was also associated with intraoperative hemodynamic changes.
Related
- Effects of dexmedetomidine nasal spray on postoperative sleep-related indicators in patients undergoing laparoscopic cholecystectomy
- Low pressure (8 mmHg) pneumoperitoneum does not significantly reduce postoperative visual analog scale score after laparoscopic cholecystectomy: Randomized trial
- Bilateral Erector Spinae Plane Block With 0.375% Ropivacaine and Postoperative Analgesia After Laparoscopic Cholecystectomy: A Prospective, Randomized, Controlled Cohort Study.
- Dual benefit of esketamine-based opioid-free anesthesia on postoperative pain and mental health outcomes in patients undergoing bariatric surgery: a randomized controlled trial.
- Evaluation of Intraperitoneal Instillation Combined with Port-Site Infiltration of 0.5% Bupivacaine for Postoperative Pain Management in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial
BibTeX
@article{zhou2026effects,
title = {{Effects of Esketamine and Magnesium Sulfate on Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Placebo-Controlled, 2×2 Factorial Trial.}},
author = {Jie Zhou and Qian Liu and Lei Wang and Lulu Shen and Wenzhuang Zheng and Chenglan Xie},
journal = {Journal of pain research},
year = {2026},
month = oct,
doi = {10.2147/jpr.s636898},
url = {https://europepmc.org/article/MED/42909966},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Effects of Esketamine and Magnesium Sulfate on Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Placebo-Controlled, 2×2 Factorial Trial.
AU - Jie Zhou
AU - Qian Liu
AU - Lei Wang
AU - Lulu Shen
AU - Wenzhuang Zheng
AU - Chenglan Xie
PY - 2026
DA - 2026/10/17
JO - Journal of pain research
DO - 10.2147/jpr.s636898
UR - https://europepmc.org/article/MED/42909966
AB - Purpose This 2×2 factorial trial aimed to evaluate the main effects and interaction of esketamine and magnesium sulfate on postoperative fatigue syndrome (POFS) in patients undergoing laparoscopic cholecystectomy (LC).Patients and methods In this randomized, double-blind, 2×2 factorial trial, 128 patients scheduled for elective LC were randomized to receive intravenous esketamine (0.25 mg/kg load, 0.125 mg/kg/h maintenance), magnesium sulfate (30 mg/kg load, 10 mg/kg/h maintenance), both, or placebo. The primary outcome was the Christensen Fatigue Scale (CFS) score on postoperative day 1 (POD 1). Secondary outcomes included longitudinal CFS and Identity-Consequence Fatigue Scale (ICFS) scores, Quality of Recovery-15 (QoR-15), pain scores, intraoperative hemodynamics, anesthetic consumption, and safety profiles. All randomized participants were included in the primary intention-to-treat analysis. Main effects and interactions were evaluated using generalized linear models (GLM), generalized estimating equations, and linear mixed-effects models. ClinicalTrials.gov: NCT07131033 (registered August 13, 2025).Results Of the 128 randomized patients, 10 were excluded, leaving 118 in the per-protocol set, which was used only as a descriptive sensitivity analysis. Based on the prespecified factorial GLM, both esketamine and magnesium sulfate exhibited significant main effects in reducing POD 1 CFS scores (esketamine: mean difference [MD], -1.12; 95% confidence interval [CI], -1.69 to -0.55; P < 0.001; magnesium sulfate: MD, -0.69; 95% CI, -1.26 to -0.12; P = 0.018), with no significant interaction (P = 0.592). In the longitudinal analysis, esketamine reduced CFS scores on POD 1 (MD, -1.17; P = 0.001), whereas the magnesium sulfate contrast at POD 1 was not statistically significant after Bonferroni correction (MD, -0.71; P = 0.300). Neither drug significantly affected ICFS scores (P > 0.05). Esketamine improved QoR-15 scores on POD 1 and POD 2, with MDs of 10.41 (P < 0.001) and 4.60 (P = 0.001) points, respectively. Magnesium sulfate improved QoR-15 scores on POD 1 by 7.48 points (P < 0.001) but not on POD 2. Both interventions decreased early postoperative pain and intraoperative propofol and remifentanil consumption (P < 0.001). Magnesium sulfate significantly prolonged extubation time (MD, 1.69 min; 95% CI, 0.26 to 3.12; P = 0.021), whereas esketamine did not reach statistical significance; neither agent significantly increased PACU stay. No significant differences were observed in prespecified adverse events.Conclusion In this 2×2 factorial trial, perioperative esketamine was associated with reduced acute postoperative fatigue and improved early recovery after laparoscopic cholecystectomy, whereas the magnesium sulfate effect was significant in the GLM model but not confirmed by the corrected longitudinal analysis. Both agents had anesthetic-sparing and early analgesic effects, and no significant esketamine-magnesium interaction was detected for the primary outcome. Magnesium sulfate was also associated with intraoperative hemodynamic changes.
SN - 1178-7090
ER -